Biotechnology News and Research RSS Feed - Biotechnology News and Research

Mice fed with omega 3 fatty acids have healthier joints

Mice fed with omega 3 fatty acids have healthier joints

Mice consuming a supplement of omega 3 fatty acids had healthier joints than those fed diets high in saturated fats and omega 6 fatty acids, according to Duke Medicine researchers. [More]
Charles H. Hennekens wins prestigious Alton Ochnser Award

Charles H. Hennekens wins prestigious Alton Ochnser Award

The Ochnser Clinic Foundation recently announced that the 29th annual recipient of the prestigious Alton Ochnser Award is Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University. [More]
Dyadic International announces details regarding new Bakenzyme project

Dyadic International announces details regarding new Bakenzyme project

Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today details regarding its new Bakenzyme project. [More]
Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. [More]
Skin cells possess olfactory receptor for sandalwood scent

Skin cells possess olfactory receptor for sandalwood scent

Skin cells possess an olfactory receptor for sandalwood scent, as researchers at the Ruhr-Universit-t Bochum have discovered. [More]
Oncolytics completes patient enrollment in phase II metastatic pancreatic cancer study

Oncolytics completes patient enrollment in phase II metastatic pancreatic cancer study

Oncolytics Biotech Inc. today announced completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045). [More]
Research on intestinal microbiota overturns vision of human gut ecosystem

Research on intestinal microbiota overturns vision of human gut ecosystem

An international research team within the MetaHIT consortium coordinated by INRA and involving teams from CEA, CNRS and Université d'Evry, has developed a new method to analyse the global genome, or the metagenome of the intestinal microbiota. [More]
Researchers map unknown microorganisms in human intestinal flora

Researchers map unknown microorganisms in human intestinal flora

Researchers from DTU Systems Biology have mapped 500 previously unknown microorganisms in human intestinal flora as well as 800 also unknown bacterial viruses (also called bacteriophages) which attack intestinal bacteria. [More]

BBSRC announce launch of Crossing Biological Membranes’ network

The BBSRC, with support from EPSRC, have committed £18M to fund 13 unique collaborative Networks in Industrial Biotechnology and Bioenergy (BBSRC NIBB). [More]
FDA grants Fast Track designation to Akashi Therapeutics' HT-100 for treatment of DMD

FDA grants Fast Track designation to Akashi Therapeutics' HT-100 for treatment of DMD

Akashi Therapeutics, Inc., announced today that the U.S. Food and Drug Administration has granted Fast Track designation to the company's most advanced product candidate, HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD. [More]
Genentech agrees to acquire Seragon Pharmaceuticals

Genentech agrees to acquire Seragon Pharmaceuticals

Genentech, a member of the Roche Group, today announced it has entered into a definitive agreement to acquire Seragon Pharmaceuticals, Inc., a privately held biotechnology company based in San Diego, California. [More]
Wyatt Technology highlights protein-protein interactions study investigated by dynamic light scattering

Wyatt Technology highlights protein-protein interactions study investigated by dynamic light scattering

Wyatt Technology Corporation, the world leader in absolute macromolecular characterization instrumentation, is pleased to highlight a study recently authored by Martin Skov Neergaard from the Faculty of Health and Medical Sciences at the University of Copenhagen, “Protein-Protein Interactions Investigated by DLS: Determination at High and Low Protein Concentration.” [More]
Research shows foodborne pathogen can cause disease in some breeds of poultry

Research shows foodborne pathogen can cause disease in some breeds of poultry

Contrary to popular belief, the foodborne pathogen Campylobacter jejuni is not a harmless commensal in chickens but can cause disease in some breeds of poultry according to research published in mBio-, the online open-access journal of the American Society for Microbiology. [More]
A*STAR scientists pioneered a molecular connection between obesity and diabetes

A*STAR scientists pioneered a molecular connection between obesity and diabetes

Scientists from the Institute of Molecular and Cell Biology, a research institute under the Agency for Science, Technology and Research, have discovered that obese individuals lack a protein that is essential for regulating blood glucose levels, causing them to face higher risks of developing diabetes. [More]
Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile) [More]

IXICO and VirtualScopics jointly lease office space in New Hope, Pennsylvania

VirtualScopics, Inc., a leading provider of clinical trial imaging solutions, and IXICO plc (AIM: IXI), the brain health company, announced today they are jointly leasing 2,190 sq. ft. of office space in New Hope, Pennsylvania, strategically located within the big pharma corridor that runs through New Jersey and Pennsylvania. [More]
Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç. [More]

Key market data on the Australia trauma fixation market

"Australia Trauma Fixation Market Outlook to 2020″, provides key market data on the Australia Trauma Fixation market. [More]
Valent Biosciences opens new biorational manufacturing facility in Iowa

Valent Biosciences opens new biorational manufacturing facility in Iowa

Valent BioSciences Corporation (VBC) today marked the official opening of its new $146 million biorational manufacturing facility in Osage, IA in a ceremony that included more than 130 international dignitaries, state and local VIPs, and media personnel. [More]
Psychostimulant increases risk of cardiovascular events in children with ADHD

Psychostimulant increases risk of cardiovascular events in children with ADHD

Psychostimulant use to treat children and adolescents with attention-deficit/hyperactivity disorder (ADHD) is increasing worldwide, and the evaluation of the cardiovascular safety of stimulant medication used in treatment has been a recent topic of concern. [More]